Abstract
Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angioplasty, Balloon, Coronary*
-
Biomarkers / blood
-
Coronary Disease / therapy*
-
Creatine Kinase / blood
-
Creatine Kinase, MB Form
-
Double-Blind Method
-
Eptifibatide
-
Humans
-
Infusions, Intra-Arterial
-
Isoenzymes / blood
-
Myocardial Infarction / blood
-
Myocardial Infarction / etiology
-
Myocardial Infarction / mortality
-
North America / epidemiology
-
Peptides / therapeutic use*
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use
-
Postoperative Complications / blood
-
Postoperative Complications / etiology
-
Postoperative Complications / mortality
-
Survival Analysis
-
Time Factors
-
Treatment Outcome
Substances
-
Biomarkers
-
Isoenzymes
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Creatine Kinase
-
Creatine Kinase, MB Form
-
Eptifibatide